Inhibition of spinal bone formation in AS: 10 years after comparing adalimumab to OASIS

Abstract

A decade has passed since the publication on the comparison of the effect of adalimumab with data from a historic cohort on the progression of structural damage in the spine of patients with ankylosing spondylitis (AS). No effect could be observed, and currently, there is still no definite proof that TNF inhibitors (TNFi) inhibit spinal structural damage. The findings of the publication are discussed within the context of the time at the publication and new developments.